Ordinance
|
Art. 8 Cantonal manufacturing licence
1 Hospital pharmacists and persons in possession of a cantonal licence in accordance with Article 30 TPA who prepare medicinal products in accordance with Article 9 paragraph 2 letters a–cbis or paragraph 2bis TPA must carry out a risk assessment in accordance with Annex 3. This provision does not apply to the cases set out in paragraph 6 below. 2 The conduct of these risk assessments should be documented. This documentation should be presented to the cantonal supervisory authority on request. 3 If the risk assessment produces a value below the threshold specified in Annex 3, a cantonal manufacturing licence is required instead of a licence issued by Swissmedic. 4 The licence is granted if it can be ensured that the rules of Good Manufacturing Practice for small quantities of medicinal products in accordance with Annex 2 are observed. 5 The cantons regulate the other conditions for the granting of the licence in accordance with paragraph 3 and periodically carry out facility checks. 6 Any person who manufactures radiopharmaceuticals requires a licence granted by Swissmedic. BGE
150 V 210 (9C_65/2023) from 18. März 2024
Regeste: Art. 25 Abs. 1 und 2 lit. b, Art. 32 Abs. 1 Satz 1, Art. 34 Abs. 1, Art. 44 Abs. 1 Satz 1, Art. 52 Abs. 1 lit. a Ziff. 2 und lit. b KVG; Art. 63 Abs. 2 KVV; ALT II (Bearbeitungstarif) lit. D Ziff. 2 (nachfolgend: ALT II D 2); Art. 4 Abs. 1 lit. a und c HMG; Herstellungstaxe. Die in Frage stehende, in der Spitalapotheke vorgenommene Aufbereitung der Zytostatika fällt unter die Herstellungstaxe gemäss ALT II D 2 ("Aseptische Zytostatika-Herstellung gemäss guter Herstellungspraxis [GMP]") und ist daher, zumal wirksam, zweckmässig und wirtschaftlich, vom obligatorischen Krankenpflegeversicherer entsprechend zu vergüten (E. 7-10). |